Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 211,772
  • Shares Outstanding, K 48,130
  • Annual Sales, $ 7,200 K
  • Annual Income, $ -51,860 K
  • 36-Month Beta 1.88
  • Price/Sales 29.10
  • Price/Cash Flow N/A
  • Price/Book 1.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +36.71%
on 04/26/18
4.70 -5.47%
on 05/16/18
+0.99 (+28.79%)
since 04/24/18
3-Month
2.80 +58.68%
on 03/01/18
4.70 -5.47%
on 05/16/18
+1.19 (+36.71%)
since 02/23/18
52-Week
2.80 +58.68%
on 03/01/18
13.05 -65.95%
on 07/27/17
-3.16 (-41.54%)
since 05/24/17

Most Recent Stories

More News
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

-- 1 global Phase 3 trial focused on synovial sarcoma patients

IMDZ : 4.44 (+0.98%)
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1

Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.

PTGX : 6.55 (+2.02%)
LGND : 191.22 (+0.25%)
IMDZ : 4.44 (+0.98%)
SNY : 38.60 (-0.03%)
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update

-- The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3

IMDZ : 4.44 (+0.98%)
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .

CELG : 79.57 (+2.46%)
IMDZ : 4.44 (+0.98%)
GILD : 67.36 (-1.19%)
PFE : 35.92 (-0.14%)
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update

Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report first quarter 2018 financial results after the close of U.S....

IMDZ : 4.44 (+0.98%)
Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?

Immune Design (IMDZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMDZ : 4.44 (+0.98%)
Report: Developing Opportunities within VAREX IMAGING, Movado Group, Equity Bancshares, Huntington Ingalls Industries, Immune Design, and Westwood Holdings Group -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of VAREX IMAGING (NASDAQ:VREX),...

MOV : 40.65 (+2.91%)
EQBK : 40.06 (-0.82%)
VREX : 37.73 (+0.51%)
WHG : 58.92 (-0.13%)
IMDZ : 4.44 (+0.98%)
HII : 227.36 (+2.20%)
Immune Design Poised on Progress of Pipeline Candidates

Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.

MRK : 59.10 (-0.12%)
IMDZ : 4.44 (+0.98%)
RHHBY : 27.5900 (+0.18%)
SNY : 38.60 (-0.03%)
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4

Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.

IMDZ : 4.44 (+0.98%)
RHHBY : 27.5900 (+0.18%)
REGN : 295.04 (-0.09%)
SNY : 38.60 (-0.03%)
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

- New positive clinical and translational data for both lead agents

IMDZ : 4.44 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade IMDZ with:

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Key Turning Points

2nd Resistance Point 4.70
1st Resistance Point 4.55
Last Price 4.44
1st Support Level 4.25
2nd Support Level 4.10

See More

52-Week High 13.05
Fibonacci 61.8% 9.13
Fibonacci 50% 7.93
Fibonacci 38.2% 6.72
Last Price 4.44
52-Week Low 2.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar